Aytu Bioscience (AYTU) versus Intec Pharma (NTEC) Head-To-Head Comparison

Aytu Bioscience (NASDAQ:AYTU) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.


This table compares Aytu Bioscience and Intec Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aytu Bioscience -277.44% -148.91% -62.63%
Intec Pharma N/A -63.39% -57.89%

Valuation and Earnings

This table compares Aytu Bioscience and Intec Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aytu Bioscience $3.66 million 0.59 -$10.18 million ($27.94) -0.04
Intec Pharma N/A N/A -$29.09 million ($1.65) -3.58

Aytu Bioscience has higher revenue and earnings than Intec Pharma. Intec Pharma is trading at a lower price-to-earnings ratio than Aytu Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Aytu Bioscience and Intec Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu Bioscience 0 0 1 0 3.00
Intec Pharma 0 0 5 0 3.00

Aytu Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 740.34%. Intec Pharma has a consensus price target of $12.88, indicating a potential upside of 118.22%. Given Aytu Bioscience’s higher probable upside, research analysts plainly believe Aytu Bioscience is more favorable than Intec Pharma.

Risk and Volatility

Aytu Bioscience has a beta of 6.68, meaning that its stock price is 568% more volatile than the S&P 500. Comparatively, Intec Pharma has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

45.1% of Intec Pharma shares are owned by institutional investors. 5.8% of Aytu Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

About Aytu Bioscience

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply